Joe Palca

Joe Palca is a science correspondent for NPR. Since joining NPR in 1992, Palca has covered a range of science topics — everything from biomedical research to astronomy. He is currently focused on the eponymous series, "Joe's Big Idea." Stories in the series explore the minds and motivations of scientists and inventors. Palca is also the founder of NPR Scicommers – A science communication collective.

Palca began his journalism career in television in 1982, working as a health producer for the CBS affiliate in Washington, DC. In 1986, he left television for a seven-year stint as a print journalist, first as the Washington news editor for Nature, and then as a senior correspondent for Science Magazine.

In October 2009, Palca took a six-month leave from NPR to become science writer in residence at The Huntington Library, Art Collections, and Botanical Gardens.

Palca has won numerous awards, including the National Academies Communications Award, the Science-in-Society Award of the National Association of Science Writers, the American Chemical Society's James T. Grady-James H. Stack Award for Interpreting Chemistry for the Public, the American Association for the Advancement of Science Journalism Prize, and the Victor Cohn Prize for Excellence in Medical Writing. In 2019, Palca was elected to the American Academy of Arts and Sciences for outstanding achievement in journalism.

With Flora Lichtman, Palca is the co-author of Annoying: The Science of What Bugs Us (Wiley, 2011).

He comes to journalism from a science background, having received a Ph.D. in psychology from the University of California at Santa Cruz, where he worked on human sleep physiology.

The primary goal of a COVID-19 vaccine is to keep people from getting very sick and dying. But there's another goal — to prevent the spread of the disease — and it's not clear most vaccine candidates currently under development can do that.

Some scientists think they can solve that problem by delivering a vaccine as a nasal spray.

Under normal circumstances, it could take years — if not decades — to bring a new vaccine to market. The COVID-19 pandemic has changed all that. In May, the Trump administration launched Operation Warp Speed with the goal of delivering initial doses of a safe and effective vaccine by January 2021 — shortening the development time from years to months.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

ARI SHAPIRO, HOST:

Copyright 2020 NPR. To see more, visit https://www.npr.org.

AILSA CHANG, HOST:

There are many approaches to making a vaccine against COVID-19. Some use genetic material from the coronavirus, some use synthetic proteins that mimic viral proteins and some use disabled versions of the virus itself.

But before any of these approaches can generate the antibodies to the coronavirus that scientists say are essential to protecting people from getting sick, the immune system has to be primed to make those antibodies.

That's the job of something called an adjuvant.

Nobody is eager to be stuck by a needle twice, so naturally many would view a COVID-19 vaccine that provides disease protection after a single injection as a good thing.

Two new studies released Thursday suggest that might be possible.

The COVID-19 vaccine candidate made by the U.S. biotech company Moderna and developed in collaboration with the National Institutes of Health starts its final phase of testing Monday.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

NOEL KING, HOST:

If you're planning a trip to Mars, now is the time to go.

For a month or so, Earth and Mars line up in a way that makes it possible to go from one to the other. Miss that window, and you have to wait two years for the next opportunity. The United Arab Emirates, China and the United States all have missions scheduled for launch in July.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

MARY LOUISE KELLY, HOST:

Pages